Thus, considering the role of hTERT itself as a central driving force of CRC, our current explorations at least suggest that the combinational inhibition simultaneously targeting SPT6, SND1, and hTERT might provide an alternative and novel strategy in CRC treatment. Here, SUPT6H is linked to colorectal carcinoma.